

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

Serious harms of the COVID-19 vaccines: a systematic review

Peter C Gøtzsche & Maryanne Demasi
Institute of Scientific Freedom, DK-2970 Hørsholm, Denmark

Corresponding author:
Peter C Gøtzsche
Institute for Scientific Freedom
Kløvervang 39
DK-2970 Hørsholm
Denmark

pcg@scientificfreedom.dk
+45 53642066

Abstract

Introduction: Serious harms of the COVID-19 vaccines have been underreported in published trial reports.

Methods: Systematic review of papers with data on serious adverse events (SAEs) associated with a COVID-19 vaccine.

Results: We included 18 systematic reviews, 14 randomised trials, and 34 other studies with a control group. Most studies were of poor quality. The most reliable one was a systematic review of regulatory data on the two pivotal randomised trials of the mRNA vaccines. It found significantly more SAEs of special interest with the vaccines than with placebo, and the excess risk was considerably larger than the benefit, measured as the risk of hospitalisation. The adenovirus vector vaccines increased the risk of venous thrombosis and thrombocytopenia, and the mRNA-based vaccines increased the risk of myocarditis, with a mortality of about 1-2 per 200 cases. We also found evidence of serious neurological harms, including Bell's palsy, Guillain-Barré syndrome, myasthenic disorder and stroke, which are likely due to an autoimmune reaction, as has been suggested also for the HPV vaccines. Severe harms, i.e. those that prevent daily activities, were hugely underreported in the randomised trials. These harms were very common in studies of booster doses after a full vaccination and in a study of vaccination of previously infected people.

Discussion: Serious and severe harms of the COVID-19 vaccines have been ignored or downplayed, and sometimes been deliberately excluded by the study sponsors in high impact medical journals. This area needs further study. Authorities have recommended virtually everyone get vaccinated and receive booster doses. They fail to consider that the balance between benefits and harms becomes negative in low-risk groups such as children and people who have already acquired natural immunity.

Keywords: COVID-19 vaccines, serious adverse events, harms

1. Introduction

Vaccines to prevent SARS-CoV-2 infection were considered to be the most promising approach for curbing the COVID-19 pandemic. The major drug regulators such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), authorised the first COVID-19 vaccines under emergency or conditional use in December 2020 through accelerated pathways,^{1,2} which involved a lower burden of proof for efficacy and safety than traditional approval pathways.³ The impression was that the vaccines were highly effective at preventing infection and severe disease, as only one severe case of COVID-19 occurred in the vaccine groups compared with 49 in the control groups in the three pivotal trials from Pfizer, Moderna and AstraZeneca.⁴⁻⁶ Governments commenced population-wide vaccination campaigns immediately, prior to any of the conventional phases of clinical trials had been completed or any medium or long-term harms could be elucidated.

Serious concerns have been raised about the reliability of the clinical trial data, partly because the pharmaceutical industry has a history of falsifying data and deliberately hiding harms.⁷ We have documented that incapacitating harms have been deliberately left out of the published trial reports of the COVID-19 vaccines.^{8,9} However, data from other types of research, mainly pharmacovigilance studies, have associated thrombosis, myocarditis and the Guillain-Barré syndrome with COVID-19 vaccination.¹⁰

Neither the vaccine manufacturers, nor the drug regulators have allowed independent researchers access to the raw trial data of the COVID-19 vaccines.¹¹ Transparency advocates sued the FDA for access and a court ordered the agency to release regulatory documents, but not the raw data.¹²

We performed a systematic review of the published studies on all types of COVID-19 vaccines to analyse the risk of serious harms.

2. Methods

We carried out a systematic review of systematic reviews and observational studies that included data on serious adverse events (SAEs) associated with a COVID-19 vaccine. According to the European Medicines Agency, an SAE is an adverse event that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect.

In clinical trials, drug harms are often divided into mild, moderate, and severe where severe means preventing usual activity.

We noted in our protocol that we might limit the inclusion of reviews and studies according to methodological rigour or number of patients, if the workload became excessive. This was the case, and we therefore excluded studies that addressed special groups of people, e.g. patients with inflammatory bowel disease and pregnant women; studies based on questionnaires; studies that did not have a comparator group; and randomised trials and comparative cohort studies that had less than 1000 participants. We also needed to abandon our aim of reviewing adverse events lasting at least one year, as the studies did not provide such data.

115

116 2.1 Search strategy and selection of studies

117

118 We searched PubMed on 4 April 2022 with this strategy: (COVID-19 OR SARS-CoV-2)
119 AND (vaccin*) AND (safety OR adverse event* OR harm*).

120 One researcher (MD) screened the search results by title and abstract and
121 excluded articles that clearly did not fulfil our inclusion criteria. Any records where
122 there was doubt were examined by both researchers. Next, we examined the full
123 reports for possible inclusion independently, resolving disagreements by discussion.

124

125 2.2 Data management and data extraction

126

127 We used Zotero to manage the search results and MS Excel and Word to handle the
128 extracted data. One researcher extracted data, and doubts were resolved by
129 discussion.

130 We described the risks for adverse events and focused on bias and confounders
131 in the studies. As we expected huge heterogeneity in the way the studies were
132 carried out and reported, we aimed primarily at producing a narrative review, which
133 could be useful for decision making and for planning research.

134

135 3 Results

136

137 Our search yielded 4,637 records. We initially excluded 4,074 obviously irrelevant
138 records. After browsing or reading the remaining records, we excluded another 479
139 records: 242 cohort studies without an adequate control group, 36 comparative
140 studies with less than 1000 participants, five reports with data included in other
141 papers, a study of a typhoid vaccine, a small study with a meningococcal vaccine in
142 the control group, 126 reports of single cases, 61 reports of multiple cases, five
143 reports with no cases, and two studies based on questionnaires.

144 We also excluded 26 of the 42 systematic reviews we found: 13 (including one
145 about “safety and efficacy” of the vaccines that included over 100,000 patients from
146 randomised trials)¹³ did not look for serious adverse events or reported that there
147 were none; three were in pregnancy; one from Wuhan in China did not report SAEs
148 by treatment group;¹⁴ two were about inflammatory bowel disease; one about eye
149 diseases; two were not about COVID-19 vaccines; one was a protocol; one was an
150 autopsy study that established a causal relationship in 15 of 38 deaths;¹⁵ and one
151 from Hong Kong was unreliable, as it combined data from trials with those from
152 observational studies and concluded that the 95% confidence intervals did not
153 indicate a relationship between the vaccines and SAEs, which was incorrect as
154 several confidence intervals excluded the possibility of no relationship.¹⁶

155 We included 17 systematic reviews,¹⁷⁻³³ 14 randomised trials,³⁴⁻⁴⁷ and 31 other
156 studies with a control group.⁴⁸⁻⁷⁸ Four of these were not identified in our search. A
157 systematic review¹⁷ and two registry studies^{53,78} were published after the cut off for
158 our search, and a comparative study was provided by a colleague.⁶⁶

159

160 3.1 Serious adverse events in general

161

162 The most methodologically rigorous, reliable, and relevant research paper we
163 retrieved was a systematic review conducted by researchers from USA, Spain, and
164 Australia of regulatory data on the two pivotal randomised trials of the mRNA
165 vaccines, one from Pfizer and one from Moderna.¹⁷

166 The review analysed SAEs in general and SAEs of special interest (AESI) according
167 to the Brighton Collaboration criteria adopted by the WHO.

168 The trials were expected to follow participants for two years. However, within
169 weeks of the FDA emergency use authorisation, the sponsors began to unblind the
170 participants and offered the vaccine also to those in the placebo group.¹⁷ Therefore,
171 the review authors used the interim datasets that were the basis for the emergency
172 authorisation, covering about 4 months after the trials commenced.

173 The authors included journal publications and SAEs results tables from the
174 websites of the FDA and Health Canada. Based on blinded tables, two clinicians
175 judged independently whether an SAE was also an AESI. To account for multiple SAEs
176 occurring in the same patient, a standard adjustment was used to widen the
177 confidence intervals.

178 For SAEs, the risk difference was 13.2 per 10,000 vaccinated people (95%
179 confidence interval -3.2 to 29.6) and the risk ratio was 1.16 (0.97 to 1.39).

180 For SAEs of special interest, the risk difference and the risk ratio were
181 significantly increased, 12.5 (2.1 to 22.9) and 1.43 (1.07 to 1.92), respectively. The
182 largest excess risk occurred amongst the Brighton category of coagulation disorders
183 (36 vs 23 patients). Only 6 vs 6 patients developed myocarditis/pericarditis.

184 Even though the researchers blinded their classifications, critics have claimed
185 that they should have excluded some events and excluded others. Out of curiosity,
186 the researchers redid their analyses based on this, which only rendered the results
187 slightly worse for the vaccines (Peter Doshi, personal communication).

188 The SAEs in the Moderna trial were underreported. For reasons not documented
189 in the trial protocol, Moderna included efficacy outcomes in its SAEs tabulations,
190 while Pfizer excluded them.

191 Pfizer's vaccine increased SAEs significantly, risk difference 18.0 per 10,000 (1.2
192 to 34.9) and risk ratio 1.36 (1.02 to 1.83). In contrast, FDA concluded that SAEs were
193 "balanced between treatment groups." This discrepancy may in part be explained by
194 the fact that FDA analysed participants experiencing one or more SAEs because they
195 had access to individual participant data, whereas the researchers did not, and
196 therefore analysed total SAEs. Hence, FDA's analysis did not reflect the observed
197 excess of multiple SAEs in the vaccine group. More importantly, FDA used a different
198 analysis population with different follow-up windows, which resulted in 126 vs 111
199 participants with SAEs whereas the researchers found 127 vs 93, also using FDA data.

200 In a follow-up of Pfizer's trial, 24 of the 32 authors were from Pfizer.³⁴ Even
201 though the additional data contributed to the full approval of the vaccine in the
202 United States, there were no numerical data on SAEs in the trial report in *New*
203 *England Journal of Medicine*, which just noted that no new SAEs "were considered
204 by the investigators to be related to BNT162b2" and that "No new safety signals
205 relative to the previous report were observed during the longer follow-up period."
206 This was highly misleading. The journal article specified that safety would be
207 evaluated through 6 months after the second dose, but what was published in a
208 supplement on a website was in violation of Pfizer's own protocol and the study

report. The supplement only showed data reported up to one month after the second vaccine dose. Thus, Pfizer had omitted five months of safety data. Deliberately hiding harms data could be considered fraud.

In a trial of Janssen's vaccine, 19 of the 20 authors were from Janssen.³⁵ SAEs occurred in 223 of 21,898 vs 265 of 21,890 patients, and 19 vs 2 patients had SAEs considered by the investigator to be related to vaccination. The authors noted the following imbalances in adverse events occurring within 28 days after vaccination: tinnitus (15 vs 4), urticaria (13 vs 6), convulsion (9 vs 4), pulmonary embolism (10 vs 5), and deep vein thrombosis (11 vs 3). We calculated that the vaccine reduced total mortality, 28 vs 55 deaths, risk ratio 0.51 (0.32 to 0.80), and COVID-19 related mortality, 5 vs 22 deaths, risk ratio 0.23 (0.09 to 0.60). The authors found the same but used person-years as denominators, which is a potentially flawed approach.

In a trial of AstraZeneca's vaccine, 101 of 21,587 vs 53 of 10,792 patients had an SAE within 28 days after a vaccine dose.³⁶ However, the paper specified that SAEs would be recorded from "the time of signed informed consent through day 730." As it is implausible that no one of 32,379 patients would be admitted to hospital for two years, many SAEs must be missing, not only from the trial report but also in its supplementary data. There were 7 vs 7 deaths, but yet again, not within two years but only within 28 days after each vaccination, which could also be considered fraud. Yet again, in *New England Journal of Medicine*.

A trial in India of ZyCoV-D, a DNA-based vaccine, was also highly problematic. It randomised 27,703 patients, either aged 12-17 years or 60 years and older.³⁷ A supplement reported one SAE in the vaccine group and none in the placebo group among the elderly and one vs two in "comorbid subjects." The main text was totally different, with no division as per randomised group. It described 15 SAEs, but seven of these were merely being COVID-19 positive, which is not an SAE and furthermore belongs to the reporting of the benefits, not the harms. There was one death in each group. This totally confusing paper was published in *The Lancet*.

In a UK trial of a recombinant nanoparticle vaccine (NVX-CoV2373), published in *New England Journal of Medicine*, there were 41 patients with SAEs of 7,569 in the vaccine group and 41 of 7,570 in the placebo group.³⁸ But in another table, the numbers were 44 vs 44 SAEs.

In a US-Mexican trial, also of the NVX-CoV2373 vaccine, a supplement showed that 228 of 19,729 patients had an SAE in the vaccine group and 128 of 9,853 in the placebo group.³⁹ Treatment-emergent systemic adverse events grade 4 within 7 days (which are life-threatening) were more common in the vaccine group, 17 vs 5 after first dose and 21 vs 5 after second dose. There was no mention of grade 4 events in the main text. The trial was published in *New England Journal of Medicine*.

An Indonesian trial of inactivated SARS-CoV-2 whole virion vaccine from Sinovac randomised 1620 people:⁴⁰ "there were nine serious adverse events (SAEs) that occurred in all subjects with a classification not related to vaccine products (five SAEs)." This unintelligible text was published in *Vaccine*.

A Taiwanese trial of a recombinant protein subunit vaccine (MVC-COV1901) provided no data in the article, which only stated that "No serious adverse events were considered related to the study intervention."⁴¹ However, in a supplement, 18 of 3295 patients had an SAE on the vaccine and 1 of 549 on placebo. Unsolicited adverse events grade 3 or above occurred in 93 vs 11 patients. Grade 3 was not

defined, but it is commonly defined as being serious and interfering with a person's ability to do basic things like eat or get dressed. The trial was published in *Lancet Respiratory Medicine*.

In an Indian trial of the AstraZeneca vaccine, 12 of 900 patients had an SAE on the vaccine and 2 of 300 on placebo.⁴²

Systematic reviews of mainly published trials were of poor quality and found other results. One from India included both randomised and nonrandomised studies and did not find an increase in SAEs: 0.7% in the groups treated with the AstraZeneca vaccine and 0.8% in the control groups.¹⁸ The authors stated that their search strategy, "(COVID-19 Vaccine)" retrieved 196 records, but when we repeated it for the same time period, we retrieved 3,371 records. Some of the data were also erroneous. In a table, the authors stated that there were only 4 SAEs in Pfizer's pivotal trial,⁵ but there were 126 vs 111, which they in the text described as 126 vs 11.

A Chinese review did not find an increase in the risk of SAEs, risk ratio 0.94 (0.71 to 1.25), and the vector based vaccines decreased the risk, risk ratio 0.79 (0.63 to 0.99).¹⁹

Another Chinese review only presented data in a supplement, divided by organ class, with no statistical estimates.²⁰

A review from Indonesia presented no summary data on SAEs.²¹

A review from Canada, of 25 randomised trials and 105,527 patients, only mentioned three anaphylactic shocks on the vaccine and one on placebo.²²

A US register study of nursing home residents reported lower 7-day mortality after first vaccination than among unvaccinated people, risk ratio 0.34 (0.22 to 0.54) but no difference in hospitalisations, risk ratio 0.95 (0.72 to 1.24).⁴⁸ These results are not reliable, as the researchers adjusted for 11 confounders (see Discussion).

3.2 Thromboses

Most systematic reviews were of poor quality. The Canadian review of randomised trials mentioned just above described 37 blood clots in the Results section on the AstraZeneca vaccine, but they did not come from the trials but from 17 million vaccinated people, which is 0.2 cases per 100,000.²²

A systematic review of non-randomised studies from South Korea identified 664 patients who developed vaccine-associated thrombosis with thrombocytopenia after an adenovirus vector vaccine.²³ The mean age was 46 years, 70% were females, 91% had antibodies against platelet factor 4, and 32% died. The pooled incidence of venous thrombosis after AstraZeneca's vaccine was 28 (12-52) per 100,000 doses, or 130 higher than in the Canadian study. The pooled incidence rate of cerebral venous thrombosis after the AstraZeneca vaccine was much higher than the background rate, 23 vs 0.9 per 100,000 person-years.

A systematic review from USA, mainly of case reports, identified 144 patients with thromboembolic events after the AstraZeneca vaccine.²⁴ The mean age was 21 to 68 years, 65% were females, and 75% had thrombocytopenia. Mean time for onset of symptoms was 8 days; 50% died. The denominators vary, which makes it difficult to interpret the review.

A systematic review from Pakistan of case reports identified 80 patients with cerebral venous sinus thrombosis after vaccination.²⁵ In 83% of cases, the patients had received an adenovirus vector vaccine. The mean age was 43 years, 74% were females, and 56% had antibodies against platelet factor 4. Mean time for onset of symptoms was 11 days; 39% died.

Another systematic review from Pakistan of case reports included 65 patients with thrombosis with thrombocytopenia after vaccination.²⁶ In 92% of cases, the patients had received an adenovirus vector vaccine. The mean age was 54 years, 79% were females, and 82% had antibodies against platelet factor 4. Some numbers were wrong, e.g. 36 of 51 females survived and 15 died but the percentages were 80% and 62.5% respectively. Mean time for onset of symptoms was 9 days; 37% died.

A systematic review from Qatar included mainly case reports but also five observational studies and one “multinational study.”²⁷ The authors in- and excluded studies along the way. We were unable to extract any meaningful data from this 9,641-word long article.

In a self-controlled case series study of hospital admissions and deaths based on UK register data, the risk of thrombocytopenia was increased after the AstraZeneca vaccine, incidence rate ratio 1.33 (1.19 to 1.47) and after a SARS-CoV-2 infection, 5.27 (4.34 to 6.40).⁴⁹ The risk was also increased for venous thromboembolism, 1.10 (1.02 to 1.18) and 13.86 (12.76 to 15.05), respectively, and for cerebral venous sinus thrombosis, 4.01 (2.08 to 7.71) and 13.43 (1.99 to 90.59), respectively, where the risk was also increased for Pfizer’s vaccine, 3.58 (1.39 to 9.27).

The risk of arterial thromboembolism was increased for Pfizer’s vaccine and after an infection, 1.06 (1.01 to 1.10) and 2.02 (1.82 to 2.24), respectively. The risk was also increased for ischaemic stroke, 1.12 (1.04 to 1.20) and 2.00 (1.70 to 2.35) after an infection, respectively, and for other rare arterial thrombotic events after the AstraZeneca vaccine, 1.21 (1.02 to 1.43). Censoring the data to the time before concerns about thrombosis were raised made no difference, and the incidence of coeliac disease, which was a negative control outcome, did not change.

A study from Scotland using a national cohort also found an increased risk of thrombocytopenia after the AstraZeneca vaccine, adjusted rate ratio 5.77 (2.41 to 13.83), which was confirmed in a self-controlled case series analysis, risk ratio 1.98 (1.29 to 3.02).⁵⁰

Indian researchers used the Vigibase for disproportionality analyses but their methods were doubtful and they did not explain what the COVID vaccines were compared with.⁵¹ They noted that, “based on IC₀₂₅ values, acute myocardial infarction, cardiac arrest, and circulatory collapse were associated with the vaccine used in the age group > 75 years.”

A UK study used registry data from 8 December 2020 to 18 March 2021, in which period 21 of 46 million had their first vaccination.⁵² The researchers adjusted their estimates for a total of 30 confounders, and they used lower limb fracture as a control condition unlikely to be affected by vaccination. However, there were significantly fewer fractures after vaccination. In the Discussion, the authors mention six limitations but do not discuss fractures and avoid mentioning that their data on fractures mean that their data, which were published in *PLoS Medicine*, are unreliable.

Indeed, they were. For example, the authors reported a hugely protective effect of the AstraZeneca vaccine against venous thrombosis in the elderly (at least 70 years of age), hazard ratio 0.58 (0.53 to 0.63), whereas other research shows that this vaccine causes thrombosis. Data on all-cause mortality were also implausible, e.g. a hazard ratio of 0.19 (0.19 to 0.20) after the Pfizer vaccine. It is hard to imagine that a COVID-vaccine could reduce total mortality by 80% in elderly people, as they die from so much else.

In a European-US register study, the researchers estimated incidence rate ratios in adults after propensity scores matching and calibration using 92 negative control outcomes.⁵³ The statistical methods were highly complex and involved nine confounders. Compared with Pfizer's vaccine, the AstraZeneca vaccine increased the risk of thrombocytopenia, rate ratio 1.33 (1.18 to 1.50), risk difference 8.21 (3.59 to 12.82) per 100,000 recipients. The paper is difficult to interpret because there is an enormous amount of data on various types of thromboses; the data from country to country are not consistent; there were systematic errors, especially in the US Open Claims database; and immunisation practices were different. There was no increase in myocardial infarction.

A registry study of Danish frontline workers included data from 27 Dec 2020 to 13 April 2021.⁵⁴ Even though people were their own controls, the outcomes were adjusted for 10 confounders. The AstraZeneca vaccine increased the risk of deep vein thrombosis, risk difference 8.4 (0.2 to 16.5) per 100,000 vaccinations. The Pfizer vaccine but not the AstraZeneca vaccine reduced the mortality risk, risk difference -4.2 (-8.2 to -0.1) and -1.6 (-7.2 to 4.0), respectively. These results are the direct opposite to those from the randomised trials, where the AstraZeneca vaccine lowered mortality, risk ratio 0.37 (0.19 to 0.70), which the Pfizer vaccine didn't, risk ratio 1.03 (0.63 to 1.71).⁷⁹ This suggests that when analyses are adjusted for many confounders, this may ruin the advantage of using people as their own controls.

Italian researchers used the EudraVigilance European database to compare the vaccines from AstraZeneca, Janssen and Pfizer for cardiovascular, neurological, and pulmonary events.⁵⁵ Their paper is uninterpretable. They mistakenly talk about severe adverse events, abbreviated as SAEs, when the events are serious, which is worse than just being severe; the issue with confounders didn't even appear in their 10,856 word article; the age was unknown in over half of the people vaccinated; and they presented large hazard ratios with no confidence intervals.

In a similar study by partly the same authors, the risk ratios for cerebral vein thrombosis, splanchnic vein thrombosis, thrombocytopenia, and other bleeding events in people at least 65 years of age were 2-7 times higher for the AstraZeneca vaccine than for the Pfizer vaccine, with narrow confidence intervals.⁵⁶ The data used were those added to data bank until 16 April 2021, before concern was raised about the AstraZeneca vaccine causing blood clots.

The authors noted that while EMA reported only one SAE per million vaccine doses related to blood clots and thrombocytopenia, they found 151 and 36, respectively, for the two vaccines, with 13 and 4 deaths possibly related to this. They also reported that SAEs in the categories "nervous system disorders", "gastrointestinal disorders" and "musculoskeletal and connective tissue disorders" occurred 9 times more often with the AstraZeneca vaccine than with the Pfizer

vaccine but listed no confidence intervals. Yet again, they called serious events severe events.

In a French registry study of people at least 75 years old where the patients were their own controls, the researchers wrote that in the first two weeks after each dose of Pfizer's vaccine, "no significant increased risk was found for any outcome."⁵⁷ They actually found a *decreased* risk after the first dose for ischaemic stroke, relative incidence 0.90 (0.84 to 0.98) and for pulmonary embolism, 0.85 (0.75 to 0.96).

A registry study with US and Indian authors was seriously misleading.⁵⁸ The title was declarative: "Cerebral venous sinus thrombosis is not significantly linked to COVID-19 vaccines or non-COVID vaccines in a large multi-state health system," but the study was vastly underpowered and unable to detect anything. There were only 3 cases after Pfizer's vaccine and none after Moderna's vaccine. The abstract was also totally misleading. There were no numerical data, only a mention of "not significantly associated."

Italian researchers used data on cerebral vein thrombosis reported to the EudraVigilance database during the first six months of 2021.⁵⁹ The reporting rate per million people who received their first dose of vaccine was 21.6 (20.2 to 23.1) for AstraZeneca, 11.5 (9.6 to 13.7) for Janssen, 5.6 (4.7 to 6.6) for Moderna and 1.9 (1.7 to 2.1) for Pfizer. Cerebral vein thrombosis occurred alongside thrombocytopenia with all four vaccines, and the observed to expected ratio was significantly increased for all four vaccines, also using the highest estimated background incidence. Two limitations of the study are that the use of the vaccines in various age groups was not the same throughout Europe and that half of the observation period was after EMA had raised concern about possible blood clots caused by the adenovirus vector vaccines.⁸⁰

A study from India reported on 89 patients with acute coronary syndrome, 37 of whom had a prior vaccination history.⁶⁰ It is not possible to conclude anything about possible vaccine harms based on this paper.

3.3 Myocarditis and pericarditis

A systematic review from India included 2184 patients with myocarditis.²⁸ The mean age was 26 years, 73% were males, and 99% had received an mRNA-based vaccine. Mean time for onset of symptoms was 4 days. The paper is difficult to comprehend, e.g. 1339 patients had definite, probable or possible myocarditis but there were 845 more patients with myocarditis, and the percentage of patients admitted to the intensive care unit is derived from a denominator of only 1169. Six patients died among 1317 for which data were available. This is one per 200, which the authors call "only."

A systematic review from Singapore included published articles based on five vaccine safety surveillance databases and 52 case reports totalling 200 cases of possible COVID-19 vaccine-related myocarditis.²⁹ The authors tried to cover too much ground in one article, which makes it difficult to read, and what they found was not new and has been better described by other authors.

A systematic review with European authors included 129 cases,³⁰ but cannot be used for a risk assessment.

A systematic review of myocarditis after an mRNA vaccine included data from 69 patients based on case reports and case series.³¹ The mean age was 21 years, 93% were males, and 89% developed symptoms after the second dose. Patients were admitted to hospital a median of three days post-vaccination.

A systematic review from China of children and adolescents included both randomised trials, observational studies, and case reports.³² The authors “summarized the basic information of 27 cases from included studies,” which did not allow a risk assessment.

In a self-controlled case series study of hospital admissions and deaths based on UK registry data, the AstraZeneca vaccine and the mRNA vaccines increased the risk of myocarditis, with incidence rate ratios between 1.33 and 1.72, which were lower than the risk after a SARS-CoV-2 infection, 11.14.⁶¹

The authors confirmed their results in a similar study, which found decreased risks of cardiac arrhythmia, apart from an increase after the second dose of Moderna’s vaccine, incidence rate ratio 1.93 (1.25 to 2.96 at 1-7 days).⁶² There was no increased risk of encephalitis, meningitis and myelitis after the vaccines from AstraZeneca and Pfizer, 1.07 (0.87 to 1.31) and 1.14 (0.86 to 1.51), respectively, whereas infection increased the risk, 2.07 (1.78 to 4.11).

A French disproportionality study of myocarditis and pericarditis after an mRNA vaccine reported to VigiBase, the WHO’s pharmacovigilance database, included data till 30 June 2021.⁶³ Compared with older patients, myocarditis was much more commonly reported in young people; the reporting odds ratio (ROR) was 22.3 (19.2 to 25.9) for adolescents and 6.6 (5.9 to 7.5) for 18–29 years old. Myocarditis was also much more common in males, ROR 9.4 (8.3 to 10.6). Median time to onset was 3 days for myocarditis and 8 days for pericarditis; 21% of the cases were life-threatening, and 1% died. The estimated rate of myocarditis was 3.6 (3.3 to 3.9) per 100,000 fully vaccinated persons in the United States, and 7.8 (6.9 to 8.9) in young adults.

A US study using the Vaccine Adverse Event Reporting System (VAERS) found that patients with myocarditis after an mRNA vaccine reported between December 2020 and August 2021 had a median age of 21 years and that 82% were males.⁶⁴ The incidence in young males was over 10 times higher than in middle-aged males, and 82% of cases occurred after the second vaccination. The reporting rates in young adults were 30 times higher than the expected background rate. Glucocorticoids were used in 12% of the patients, but the most common treatment was nonsteroidal anti-inflammatory drugs, used in 87% of the patients. This is surprising because these drugs, despite their name, have no anti-inflammatory properties⁸¹⁻⁸³ and increase the risk of heart attacks and death.⁷

Another US VAERS study, with US and Chinese authors, came to different results even though it used the same observation period.⁶⁵ The adverse event rate in adolescents was three times higher than in the former study, which cannot be explained by inclusion also of pericarditis and by having no 7-day limit for reporting. Most cases occur within the first couple of days and myocarditis is diagnosed about 10 times as often as pericarditis.⁶⁵ The risk was greater for Pfizer’s vaccine, ROR 5.4 (4.1 to 7.0) than for Moderna’s, ROR 2.9 (2.2 to 3.8), but, as the authors noted, only Pfizer’s vaccine was approved for use in minors where the risk is greatest, and the risks were similar in other age groups.

The authors wrote that Janssen's vaccine "was not associated with signals of myocarditis/pericarditis." This statement is extremely misleading. First, even though few people received this vaccine, the estimate was very close to being statistically significant, ROR 1.39 (0.99 to 1.97), which is surely a signal. Second, Janssen's vaccine was only approved for adults. Third, the authors wrote that the incidence rate was higher after the mRNA vaccines than after viral vector vaccines, but they reported that these rates were 5.98 (5.73 to 6.25) vs 5.64 (4.46 to 7.04) per million, which are similar rates, and the confidence interval for Janssen's vaccine includes the whole confidence interval for the mRNA vaccines. We looked up if the authors had a conflict of interest related to Janssen, but they declared they had none.

3.4 *Inflammatory neuropathies*

In the randomised trials, there were seven cases of Bell's palsy among people receiving an mRNA vaccine versus one among placebo recipients ($P = 0.07$), and the incidence rate was 3.5-7 times higher than the background rate.⁶⁹

This signal was also found in a self-controlled case series study of hospital admissions based on UK register data.⁶⁶ There was an increased risk of Bell's palsy, incidence rate ratio 1.29 (1.08 to 1.56), Guillain-Barré syndrome, 2.90 (2.15 to 3.92), and myasthenic disorder 1.57 (1.07 to 2.30) with the AstraZeneca vaccine. Pfizer's vaccine increased the risk of haemorrhagic stroke, 1.38 (1.12 to 1.71). The risk of neurological outcomes was also increased after infection with SARS-CoV-2. There were 4 excess cases of Guillain-Barré syndrome per million people receiving the AstraZeneca vaccine and 15 excess cases after an infection.

No such signals were found in a study using data from primary care records in the UK and Spain, not even in a series of self-controlled cases of Bell's palsy.⁶⁷ The risks for Bell's palsy, Guillain-Barré syndrome, and encephalomyelitis were lower than expected background rates or about the same for the vector based and mRNA vaccines.

A case-control study from Israel with 37 cases of facial nerve palsy did not find an association to Pfizer's vaccine, odds ratio 0.84 (0.37 to 1.90).⁶⁸

An Israeli register study of Pfizer's vaccine compared the rates of Bell's palsy with background rates.⁶⁹ The standardised incidence ratio after the first dose was 1.36 (1.14 to 1.61). This is a weak signal in a study with a historical control. Expected cases cannot be determined with sufficient precision and they vary over time. The signal was even weaker after the second dose, 1.16 (0.99 to 1.36). In elderly females where the strongest association was observed in this study, the excess risk of Bell's palsy was estimated to be 5 cases per 100,000 vaccinees.

Another Israeli register study matched vaccinated with unvaccinated people for seven factors and adjusted for socioeconomic status for which matching was poor.⁷⁰ Pfizer's vaccine did not increase the occurrence of Bell's palsy, risk ratio 0.96 (0.54 to 1.70) or Guillain-Barré syndrome (1 vs 0 cases), whereas there were more cases of numbness or tingling, risk ratio 1.22 (1.08 to 1.37).

Using Vigibase for disproportionality analyses, Swiss researchers found *lower* risks for COVID-19 vaccines than for other viral vaccines for neuralgic amyotrophy, ROR 0.23 (0.17 to 0.30) vs 0.12 (0.09 to 0.16), and for Guillain-Barré syndrome, ROR

0.15 (0.13 to 0.16) vs 0.06 (0.05 to 0.06).⁷¹ In contrast, Bell's palsy was more frequently reported with COVID-19 vaccines, ROR 1.12 (1.07 to 1.17).

Indian researchers also used Vigibase for disproportionality analyses, but their methods and conclusions were doubtful.⁷² They referred to IC₀₂₅ values without explaining what it meant and did not state what the COVID vaccines were compared with. They listed 52 neurological diagnoses, which they "considered to be associated with the administration of the vaccine."

A systematic review from Kuwait and Egypt was also problematic, e.g. there was no reproducible search strategy,³³ which is essential for systematic reviews. The authors reported on 32 cases of CNS demyelination following various COVID-19 vaccines.

A study based on 555 reports in VAERS of hearing loss did not find an increase in risk, compared to the background rate.⁷³

3.5 Serious adverse events in people with previous infection

In an Israeli study, Pfizer's vaccine was given to 78 people with a previous COVID-19 infection and to 177 matched controls.⁷⁴ Some numbers and percentages are erroneous. Emergency department visit or hospitalisation was required for 5 (6%) vs 1 patients (0.6%). Even though the authors showed in a table that this difference was statistically significant ($P = 0.01$), they concluded that the vaccine was safe in people with previous infection. This is not correct. Hospitalisation is a serious harm, and harms occurred ten times as often if the patients had been infected earlier, suggesting that those with acquired immunity are at higher risk of experiencing SAEs post vaccination.

3.6 Serious adverse events after a booster dose

In a US study, 305 people previously vaccinated with two doses of 100 µg of Pfizer's vaccine received a third, booster dose and were compared with the second dose of the vaccine in 584 historical controls and with a 50 µg booster in separate studies.⁷⁵

The 100 µg booster caused more local and systemic adverse reactions than the second 100 µg vaccine dose and the 50 µg booster. A supplement showed that there was a large difference for moderate or severe solicited systemic adverse reactions; 59% experienced this on the 100 µg booster vs 39% on the 50 µg booster ($P = 0.000,05$, our calculation). There was no such difference between the 100 µg booster and the 100 µg second dose, 59% vs 54% ($P = 0.12$).

There were two serious adverse events (not six, as the authors claim, as the other four were asymptomatic infections with positive tests) but no information about which groups they came from.

In another US study, the patients used v-safe, a voluntary, smartphone-based safety surveillance system developed by the Centers for Disease Control and Prevention to provide information on adverse reactions after vaccination.⁷⁶ The occurrence of adverse reactions was very similar for dose three and dose two (99.7% of the doses were mRNA vaccines). There were many severe adverse events: 28% were unable to perform normal daily activities after the booster; 11% were unable to work or attend school; 0.2% had an emergency visit; and 0.1% were hospitalised.

In a US study of Pfizer's vaccine, organised by Pfizer, patients were randomised to receive a third dose or placebo.⁴³ The study was published in *New England Journal of Medicine*, and 24 of the 32 authors were from Pfizer or hired by Pfizer. After a third dose, 16 of 5,055 patients had an SAE on the vaccine and 24 of 5,020 on placebo.

In contrast, in a self-controlled case series study of hospital admissions based on UK registry data, the risk of myocarditis was increased after a booster dose of Pfizer's vaccine, incidence rate ratio 1.72 (1.33 to 2.22).⁶¹

A UK study of 2,878 people was uninterpretable, as they were randomised to 12 different groups including a meningococcal vaccine and as there were only 24 SAEs.⁴⁴

3.7 Serious adverse events in children

We found three randomised trials with data on SAEs in children. In all cases, the data were hidden in supplements to the article. In two trials of mRNA vaccines, 6 of 2486 vs 2 of 1240 children 12-17 years of age and 4 of 1131 vs 1 of 1129 children 12-15 years of age had SAEs, respectively.^{45,46} In a trial of a Chinese attenuated virus, the term SAEs was not used but the numbers for grade 3 reactions were 1 of 251 vs 0 of 84 in children 6-12 years of age.⁴⁷ The pooled risk ratio for these three trials was 1.90 (0.57 to 6.29, $P = 0.29$, $I^2 = 0$).

3.8 Other issues

Appendicitis has been suggested as a possible adverse because of a numerical increase in a vaccine trial.^{53f} A US study reviewed cases of appendicitis reported to VigiBase and found 358 cases compared to 329 expected cases.⁷⁷ We explored this and found a Danish registry study that reported an adjusted risk ratio of 0.93 (0.79 to 1.11) after the first dose and 0.99 (0.84 to 1.18) after the second dose of the suspected agent, an mRNA vaccine.⁷⁸

4 Discussion

Our systematic review demonstrates the difficulty of determining vaccine related SAEs in published trial data. Theoretically, systematic reviews of randomised trials should be the most reliable source of evidence, but serious harms are vastly underreported, if reported at all, in published drug trials.⁷

The underreporting seems to be particularly pronounced in vaccine trials.^{8,9,84} For the COVID-19 vaccines, there is the additional problem that, within weeks of the vaccines receiving an emergency use authorisation, when far too little time had elapsed to identify late occurring or diagnosed harms, the unblinding of trials commenced and placebo recipients were offered the vaccine.⁸⁵

The safety of vaccines is important because they are preventive, but editors of our most prestigious journals chose to relegate the data on serious harms to supplements, which few readers will access, particularly if they read the paper version.

Severe harms – which are defined as those preventing usual activity – have also been vastly underreported in the published trial reports. Pfizer’s pivotal trial report, published in *New England Journal of Medicine*, was highly misleading.⁵ It mentioned only serious adverse events considered related to the vaccine: four in the vaccine group and none in the placebo group, but, according to FDA, there were 126 vs 111 SAEs.¹⁷ Pfizer’s article was also obscure for severe adverse events. A supplement showed that 240 patients (1.1%) had severe events on the vaccine versus 139 (0.6%) on placebo. Pfizer did not provide a P-value, but $P = 2 \times 10^{-7}$. The number needed to vaccinate to harm one patient severely was only 200, which Pfizer’s article said nothing about, only that “The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache.”

In AstraZeneca’s trials, 86% of the controls did not receive placebo but another vaccine,⁴ which means that the harms of its COVID-19 vaccine cannot be estimated, as all vaccines cause harms. The pivotal trial report noted that serious adverse events were less common after the COVID-19 vaccine than after the control vaccine, 79 vs 89 patients.⁴ The rate of severe adverse events was 1% but the first 14 employees at the department of clinical microbiology at Rigshospitalet in Copenhagen where the spouse to one of us works became so ill after the AstraZeneca vaccine that all of them required a sick leave. The discrepancy between 100% in practice and 1% in the report in *The Lancet* is so huge that we suspect AstraZeneca committed fraud in its vaccine trials. The harms were so pronounced and common that Denmark stopped using the AstraZeneca vaccine.

The mRNA vaccines can also cause severe harms. As noted above, many people were unable to perform normal daily activities after a booster with an mRNA vaccine.⁷⁶

By far the most reliable study we identified was the systematic review that used regulatory data from the two pivotal randomised trials of the mRNA vaccines and restricted the observation period to reduce the contamination caused by offering the vaccine to patients in the placebo group.¹⁷ The researchers put their findings into perspective by comparing them with hospitalisations. The excess risk of SAEs of special interest was considerably larger than the reduced risk of hospitalisation, 10.1 vs 2.3 per 10,000 vaccinated people for Pfizer’s vaccine, and 15.1 vs 6.4 for Moderna’s vaccine. Even after the researchers adjusted for multiple events in the same patient in a sensitivity analysis, the risk was larger.

Serious adverse events are not directly comparable to hospitalisations. They are rarely lethal whereas a reduction in hospitalisations would be expected to reduce mortality. On the other hand, the lower the risk of dying, the more important the serious harms are of the vaccine. These findings are therefore important for considerations about whether vaccination should be recommended for young people.

Another low-risk group involves people who have already been infected with SARS-COV-2 and recovered, and therefore have acquired natural immunity. The issue of whether to vaccinate such people is highly pertinent since most of the vaccine related harms have been attributed to over-activation of the immune system.⁷⁴ In the only study we found of this, severe harms, defined as emergency department visit or hospitalisation, occurred ten times more often if the patients had been infected earlier.⁷⁴ Even though it was an observational study, this finding

raises serious concerns about the ubiquitous recommendations to also vaccinate people who have had a COVID-19 infection.

The vast majority of our populations, those who have been vaccinated, constitute another low-risk group. In the autumn of 2021, booster doses were being recommended,^{86,87} and in many cases mandated, worldwide. However, while it was generally accepted that the vaccines were still protective against COVID-19 hospitalisations, it was evident that protection against infection waned quickly.⁸⁸

The data underpinning the authorisation of booster doses were based on inferior observational and immune-bridging studies, and there was great uncertainty and confusion. In December 2021, EMA recommended boosters as frequently as every three months,⁸⁹ but in an extraordinary backflip only one month later warned that repeated boosters might weaken people's immune responses.⁹⁰ This has been shown to be the case for influenza vaccines. Canadian researchers, who replicated their findings in three different studies, found that people who received a seasonal influenza vaccine had an increased risk of getting infected with another strain the following year.⁹¹

For observational studies, the main problem is confounding. In a little known but ingenious study, a statistician used raw data from two randomised multicentre trials as the basis for observational studies that could have been carried out.⁹² He showed that the more variables that are included in a logistic regression, the further we are likely to get from the truth. He also found that comparisons may sometimes be *more* biased when the groups appear to be comparable than when they do not; that adjustment methods rarely adjust adequately for differences in case mix; and that all adjustment methods can on occasion increase systematic bias. He warned that no empirical studies have ever shown that adjustment, on average, reduces bias.⁹²

Another main problem is underreporting, particularly when doctors have been reassured by authoritative messages that the vaccines are safe. In addition, there is a fear among doctors that they can be threatened with disciplinary action if they do anything that could undermine the government's COVID-19 vaccine rollout. We have had contact with a junior doctor working in the emergency department of a major hospital who began noticing patients being rushed in with what he suspected to be serious COVID-19 vaccine injuries. His colleagues dismissed the symptoms as unrelated to the vaccine, but he felt his patients' observations were valid. He decided to write up a report and submit it to the drug regulator but was discouraged by his head of the department as there was no protocol in place for reporting vaccine injuries. Moreover, as many doctors are stressed and overworked and do not have time to fill out the paper work, very little gets reported.

Underreporting is prevalent when the event is common in the general population, e.g. thrombosis in the elderly. Overreporting can also occur, e.g. because of increased attention related to a particular harm. In mid-March 2020, EMA warned about blood clots possibly being caused by the AstraZeneca vaccine,⁸⁰ but the warning was downplayed so much that it was unlikely to inflate reports about vaccine injuries. EMA not only stated that "the vaccine is not associated with an increase in the overall risk of blood clots" but even that there had been *fewer* thromboembolic events than expected, both in studies before licensing and in reports after rollout of vaccination campaigns. However, EMA also noted that there

had been 12 cases of cerebral venous sinus thrombosis and that only 1.4 cases was expected.

It is pretty unreliable to estimate expected rates. A register study found that the incidence of deep vein thrombosis in women aged 35-54 years was five times higher in USA than in Spain.⁹³ The researchers also observed large variations between electronic health records and claims data sources when using the same analysis and outcome definitions. Other studies have reported a 10-fold difference in rates of transverse myelitis; a 38 times higher rate of Bell's palsy in USA than in Italy; and a 12-fold to a 190-fold difference in rates of narcolepsy between USA and Europe.⁹³

Many of the studies we reviewed were of very poor quality and published in journals that failed to identify fundamental errors. In 2021, for example, *Vaccines* (distinct from the respected journal *Vaccine*) published an article claiming that COVID-19 vaccines kill about as many as they save, but the authors made the basic error of assuming that all reported deaths following vaccination in pharmacovigilance data are caused by the vaccine.⁹⁴ Tensions after its publication led to the resignation of six editors and the article was retracted a week later.⁹⁵

Another example, from the same journal, was an abstract from an article we excluded, which noted that "about 50.88%" reported side effects.⁹⁶ It was not "about," but precisely 50.88%, and one should not give two decimals. We calculated that the confidence interval is 47% to 55%. Furthermore, the harms were divided into mild, moderate, and severe, where mild meant lasting less than 24 hours, moderate from 24 to 72 hours, and severe more than a week. There was no category for harms lasting more than 3 and less than 8 days, and duration it not a sign of severity. A mild harm can last for weeks, and a life-threatening harm can disappear in a few minutes, e.g. an anaphylactic shock.

A systematic review used the Jadad 5-point scale for scoring the "quality" of the randomised trials.²² The authors claimed to have adhered to the PRISMA guidelines, but these say that "scales that numerically summarise multiple components into a single number are misleading and unhelpful."⁹⁷ The Jadad scale has not been recommended for the last 25 years. This review was also published in *Vaccines*.

Despite their shortcomings, we can draw some firm conclusions based on the studies we reviewed.

The adenovirus vector vaccines increase the risk of venous thrombosis and thrombocytopenia whereas we did not find reliable data in our search to suggest that COVID-19 vaccines increase the risk of arterial thrombosis. However, this area develops quickly. Our search on 4 April 2022 identified 4637 records but this number had increased by 2816 already on 2 December. A colleague notified us of a recent Israeli register study that raises concerns.⁹⁸ It found an increase of over 25% in people aged 16-39 years in both cardiac arrest and acute coronary syndrome that was closely related to vaccination rates whereas there was no relation to COVID-19 infection rates. A so-called Reuters Fact Check concluded that their study was misleading because it did not prove that this increase was caused by the vaccines.⁹⁹ However, these researchers stated clearly in their paper that they had not established a causal relationship.

Infections and vaccines, e.g. against smallpox,¹⁰⁰ can cause myocarditis, which is also the case for mRNA-based COVID-19 vaccines, particularly in young males. The mortality is about 1-2 per 200 cases.^{28,63}

Based on biological plausibility and temporal association, inflammatory neuropathies like neuralgic amyotrophy, Bell's palsy, and the Guillain-Barré syndrome, have been linked to other vaccines, most often to the influenza vaccine.⁷¹ The mounting cases of the Guillain-Barré syndrome in 1976 were closely related to the use of a swine influenza vaccine.¹⁰¹ However, serious neuropathies can be very difficult to detect. For example, it took a long time before it was accepted that the influenza vaccine Pandemrix causes narcolepsy.^{102,103}

When our research group analysed the clinical study reports of the HPV vaccines submitted to EMA for marketing authorisation, we showed a statistically significant increase in serious neurological adverse events.¹⁰⁴ EMA denied this but based its conclusion on the data provided to the agency by the manufacturers. They did not check if this reporting was accurate despite knowing that one of the companies had previously been deceptive with its HPV vaccine harms data.^{9,105}

We found evidence of serious neurological harms, and a survey of 508 US patients suffering from persistent neurological symptoms after a COVID-19 vaccine showed a wide array of symptoms of which painful neuropathy/paraesthesias were the worst.¹⁰⁶ Prior to the vaccination, 94% of the patients had never reacted to a vaccine. Since the symptoms are so varied, doctors tend to dismiss them and conclude that the patients suffer from a psychiatric problem. However, this is unlikely. Researchers from the US National Institutes of Health studied 23 self-referred patients who reported new neuropathic symptoms beginning within three weeks after SARS-CoV-2 vaccination (for 9 patients, after the second dose).¹⁰⁷ All patients had sensory symptoms comprising severe face or limb paraesthesias, and 12 had objective evidence of small-fiber peripheral neuropathy. Autonomic testing in 12 identified 7 with reduced distal sweat production and 6 with postural orthostatic tachycardia syndrome.

Some patients have experienced similar symptoms after an HPV vaccine, which suggests autoimmunity directed against the autonomic nervous system. In a Danish study, antibodies directed against the adrenergic β -2 receptor were found in 75% of 108 patients with symptoms and in only 17% of 98 age- and sex-matched vaccinated controls ($P < 0.001$).¹⁰⁸ Antibodies against the muscarinic M-2 receptors were found in 82% vs 16% ($P < 0.001$) and against either β -2 or M-2 receptors in 92% vs 19% ($P < 0.001$). Similar symptoms and neuroendocrine antibodies have been reported in patients suffering from long-term complications after SARS-CoV-2 infection.¹⁰⁸⁻¹¹⁰

SARS-CoV-2 infection can cause transverse myelitis, with acute onset of paralysis, sensory level, and sphincter deficits due to spinal cord lesions demonstrated by imaging.¹¹¹ The occurrence of 2 reported cases among 5,807 participants within two weeks after vaccination in the pivotal AstraZeneca trial,^{4,111} is an extremely high incidence considering a worldwide incidence of 0.5 cases per million after infection.¹¹¹

SAEs have been systematically eliminated from the pivotal trials.⁸ In the Pfizer and AstraZeneca vaccine trials, participants were given digital apps to record adverse events remotely, but the apps only allowed the participants to record what the company deemed as "expected" events. If they developed thrombosis, myocarditis, Guillain-Barré Syndrome, transverse myelitis, or other serious neurological events, there was no option for them to record it on the app.

Brianne Dressen, a participant in an AstraZeneca trial, became disabled after her first injection.⁸ She is still disabled today, but there is no mention of this in the trial report in *New England Journal of Medicine*.³⁶ As Dressen was concerned about the lack of reporting of her serious adverse event (and others) in the trial's publication, she wrote to Dr Eric Rubin, editor in chief of the journal, and asked for the inaccuracies to be corrected and demanded complete reporting of the results. Rubin refused to correct the inaccurate data in his journal. The full email exchange has been made public.⁸

When Pfizer had recruited 12-15 year olds for its mRNA vaccine trial, the published data in *New England Journal of Medicine* stated that there were "no serious vaccine-related adverse events."⁴⁶ One of the participants, however, was 13 year old Maddie De Garay who suffered a serious adverse reaction following her first injection, which left her in a wheelchair and fed by a nasogastric tube.⁸ She was referred to hospital for a full assessment and a doctor diagnosed her with a "functional disorder." This doctor decided she had a pre-disposition to hysteria, and she was referred to a mental health facility. Professor and psychiatrist David Healy subsequently conducted a thorough review of her medical records, including an interview with her family, and found no such history of pre-existing conditions or mental illness.

Even if data are honestly reported, it is extremely difficult to find rare events in randomised trials. One would need a trial with 30,000 people in the vaccine arm to have a 95% chance of detecting a serious harm if it occurs in 1 of 10,000 cases,¹¹² and one case is not enough to establish a cause-effect relationship.

A rare condition is multisystem inflammatory syndrome in children. A survey of 21 people aged 12–20 years found a reporting rate of one case per million after vaccination whereas the incidence among unvaccinated people in this age group who have had a SARS-CoV-2 infection is about 200 cases per million.¹¹³

An important issue, which has received virtually no attention, is that vaccines have non-specific effects, which are very different for live attenuated vaccines and for non-live vaccines. Peter Aaby and co-workers have shown in several studies, that live attenuated vaccines, e.g. against measles, polio and tuberculosis, decrease mortality from other infections than the targeted one, whereas non-live vaccines increase mortality.^{84, 114}

Aaby's team has also analysed the randomised trials of the COVID-19 vaccines. They found that the adenovirus vector vaccines reduced total mortality, risk ratio 0.37 (0.19 to 0.70), in contrast to the mRNA vaccines, risk ratio 1.03 (0.63 to 1.71).⁷⁹ The difference between the two estimates was statistically significant ($P = 0.03$). It is a missed opportunity that nowhere in the world was the vaccine roll-out done as part of a randomised trial that could tell us if some vaccines lower mortality more than others. But now that boosters are being recommended, such trials should be performed. There is also a need for additional placebo-controlled trials, e.g. in people who have already been infected.

Another missed opportunity is that the drug regulators and other authorities have been very slow in following up signals of serious harms. In July 2021, based on medical claims data in older Americans, FDA reported detecting four potential adverse events of interest: pulmonary embolism, myocardial infarction, immune thrombocytopenia, and disseminated intravascular coagulation after Pfizer's

vaccine.¹⁷ FDA stated it would further investigate the findings, but the agency did not disclose its data, did not warn the doctors or the public, and 1½ years later, had still not updated its findings.¹¹⁵

The US Centers for Disease Control and Prevention were also slow. A study using VAERS and EudraVigilance comparing the disproportionality of adverse event reports for the influenza vaccine and the mRNA COVID-19 vaccines reported excess risks for four Brighton serious adverse events of special interest: cardiovascular events, coagulation events, haemorrhages, gastrointestinal events, and thromboses.^{115,116} CDC published a protocol in early 2021 for disproportionality analyses in the VAERS database,¹⁷ but they have not reported the results.

Given all the difficulties, obstacles with getting access to regulatory data, obfuscations, and documented underreporting, we find it likely that there are other serious harms than those uncovered so far.

This area needs further study. Authorities have recommended virtually everyone get vaccinated and receive booster doses, and fail to consider that the balance between benefits and harms becomes negative in low-risk groups such as children and people who have already acquired natural immunity.

Author contributions

Both authors had full access to all of the data and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Gøtzsche.

Protocol: both authors.

Acquisition of data: both authors.

Analysis and interpretation: both authors.

Statistical analysis: Gøtzsche.

Drafting of the manuscript: Gøtzsche.

Critical revision of the manuscript for important intellectual content: both authors.

Funding

Institute for Scientific Freedom and a private funder requesting anonymity, a retired filmmaker with no conflicts of interests in relation to our review.

Conflicts of interest

None.

Ethical review statement

Not relevant.

References

1 FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use
 Authorization for First COVID-19 Vaccine. 2020 Dec 11.
<https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19>
 (accessed 2022 Nov 30).

2 EMA recommends first COVID-19 vaccine for authorisation in the EU. 2020 Dec
 21. <https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu> (accessed 2022 Nov 30).

3 Demasi M. From FDA to MHRA: are drug regulators for hire? *BMJ* 2022 Jun
 29;377:o1538. <https://doi.org/10.1136/bmj.o1538>.

4 Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al.
 Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-
 CoV-2: an interim analysis of four randomised controlled trials in Brazil, South
 Africa, and the UK. *Lancet* 2021 Jan 9;397:99-111. DOI: [10.1016/S0140-6736\(20\)32661-1](https://doi.org/10.1016/S0140-6736(20)32661-1).

5 Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety
 and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* 2020 Dec
 31;383(27):2603-15. DOI: [10.1056/NEJMoa2034577](https://doi.org/10.1056/NEJMoa2034577).

6 Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak S, et al. Efficacy and
 safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Engl J Med* 2021;384:403-16.
 DOI: [10.1056/NEJMoa2035389](https://doi.org/10.1056/NEJMoa2035389).

7 Gøtzsche PC. Deadly medicines and organised crime: How big pharma has
 corrupted health care. London: Radcliffe Publishing; 2013.

8 Demasi M. Are adverse events in Covid-19 vaccine trials under-reported?
 Maryanne Demasi's blog. 2021 Nov 24.
<https://maryannedemasi.com/publications/f/are-adverse-events-in-covid-19-vaccine-trials-under-reported> (accessed 2022 Nov 30).

9 Gøtzsche PC. The Chinese virus: Killed millions and scientific freedom.
 Copenhagen: Institute for Scientific Freedom; 2022.

10 Rosenblum HG, Hadler SC, Moulia D, Shimabukuro TT, Su JR, Tepper NK, et al.
 Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult
 Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines
 (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on
 Immunization Practices - United States, July 2021. *MMWR Morb Mortal Wkly*
 Rep 2021;70:1094-9. DOI: [10.15585/mmwr.mm7032e4](https://doi.org/10.15585/mmwr.mm7032e4).

11 Doshi P, Godlee F, Abbasi K. Covid-19 vaccines and treatments: we must have
 raw data, now *BMJ* 2022;376:o102. doi: <https://doi.org/10.1136/bmj.o102>.

12 Demasi M. FDA to release Pfizer data but the devil could be in the detail. 2022 Jan 8. <https://maryannedemasi.substack.com/p/fda-to-release-pfizer-data-but-the-devil-could-be-in-the-detail> (accessed 2022 Nov 30).

13 Ling Y, Zhong J, Luo J. Safety and effectiveness of SARS-CoV-2 vaccines: A systematic review and meta-analysis. J Med Virol 2021;93:6486-95. DOI: [10.1002/jmv.27203](https://doi.org/10.1002/jmv.27203).

14 Xing K, Tu XY, Liu M, Liang ZW, Chen JN, Li JJ, et al. Efficacy and safety of COVID-19 vaccines: a systematic review. Zhongguo Dang Dai Er Ke Za Zhi 2021;23:221-8. <https://pubmed.ncbi.nlm.nih.gov/33691913/>.

15 Sessa F, Salerno M, Esposito M, Di Nunno N, Zamboni P, Pomara C. Autopsy Findings and Causality Relationship between Death and COVID-19 Vaccination: A Systematic Review. J Clin Med 2021;10:5876. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330010/>.

16 Fan YJ, Chan KH, Hung IF. Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3. Vaccines (Basel) 2021;9:989. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473448/>.

17 Fraiman J, Erviti J, Jones M, Greenland S, Whelan P, Kaplan RM, et al. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine 2022;40:5798-5805. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428332/>.

18 Kaur RJ, Dutta S, Bhardwaj P, Charan J, Dhingra S, Mitra P, et al. Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review. Indian J Clin Biochem 2021;36:427-39. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997788/>.

19 Cheng H, Peng Z, Luo W, Si S, Mo M, Zhou H, et al. Efficacy and Safety of COVID-19 Vaccines in Phase III Trials: A Meta-Analysis. Vaccines (Basel) 2021;9:582. doi: 10.3390/vaccines9060582. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228087/>.

20 Wu Q, Dudley MZ, Chen X, Bai X, Dong K, Zhuang T, et al. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Med 2021;19:173. doi: 10.1186/s12916-021-02059-5. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315897/>.

21 Yuniar CT, Pratiwi B, Ihsan AF, Laksono BT, Risfayanti I, Fathadina A, et al. Adverse Events Reporting Quality of Randomized Controlled Trials of COVID-19 Vaccine Using the CONSORT Criteria for Reporting Harms: A Systematic Review. Vaccines (Basel) 2022;10:313. doi: 10.3390/vaccines10020313. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875800/>.

1002 22 Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Razizadeh MH, Turner
1003 DL, et al. Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and
1004 Meta-Analysis of Randomized Clinical Trials. *Vaccines (Basel)* 2021 May 6;9:467.
1005 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8148145/>.
1006
1007 23 Kim AY, Woo W, Yon DK, Lee SW, Yang JW, Kim JH, et al. Thrombosis patterns
1008 and clinical outcome of COVID-19 vaccine-induced immune thrombotic
1009 thrombocytopenia: A Systematic Review and Meta-Analysis. *Int J Infect Dis*
1010 2022;119:130-9. doi: 10.1016/j.ijid.2022.03.034.
1011 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942584/>.
1012
1013 24 Matar RH, Than CA, Nakanishi H, Daniel RS, Smayra K, Sim BL, et al. Outcomes
1014 of patients with thromboembolic events following coronavirus disease 2019
1015 AstraZeneca vaccination: a systematic review and meta-analysis. *Blood Coagul*
1016 *Fibrinolysis* 2022;33:90-112.
1017 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8815637/>.
1018
1019 25 Jaiswal V, Nepal G, Dijamco P, Ishak A, Dagar M, Sarfraz Z, et al. Cerebral
1020 Venous Sinus Thrombosis Following COVID-19 Vaccination: A Systematic
1021 Review. *J Prim Care Community Health* 2022;13:21501319221074450.
1022 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841914/>.
1023
1024 26 Hafeez MU, Ikram M, Shafiq Z, Sarfraz A, Sarfraz Z, Jaiswal V, et al. COVID-19
1025 Vaccine-Associated Thrombosis With Thrombocytopenia Syndrome (TTS): A
1026 Systematic Review and Post Hoc Analysis. *Clin Appl Thromb Hemost*
1027 2021;27:10760296211048815.
1028 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552386/>.
1029
1030 27 Al-Ali D, Elshafeey A, Mushannen M, Kawas H, Shafiq A, Mhaimeed N, et al.
1031 Cardiovascular and haematological events post COVID-19 vaccination: A
1032 systematic review. *J Cell Mol Med* 2022;26:636-53. doi: 10.1111/jcmm.17137.
1033 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817142/>.
1034
1035 28 Goyal M, Ray I, Mascarenhas D, Kunal S, Sachdeva RA, Ish P. Myocarditis post
1036 SARS-CoV-2 vaccination: a systematic review. *QJM* 2022 Mar 3:hcac064. doi:
1037 10.1093/qjmed/hcac064. Epub ahead of print.
1038 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903459/>.
1039
1040 29 Lee ASY, Balakrishnan IDD, Khoo CY, Ng CT, Loh JKK, Chan LL, Teo LLY, Sim
1041 DKL. Myocarditis Following COVID-19 Vaccination: A Systematic Review
1042 (October 2020-October 2021). *Heart Lung Circ* 2022;31:757-65. doi:
1043 10.1016/j.hlc.2022.02.002.
1044 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874750/>.
1045
1046 30 Bellos I, Karageorgiou V, Viskin D. Myocarditis following mRNA Covid-19
1047 vaccination: A pooled analysis. *Vaccine* 2022;40:1768-74. doi:
1048 10.1016/j.vaccine.2022.02.017. <https://pubmed.ncbi.nlm.nih.gov/35153093/>.
1049

- 1050 31 Matta A, Kunadharaju R, Osman M, Jesme C, McMiller Z, Johnson EM, et al.
1051 Clinical Presentation and Outcomes of Myocarditis Post mRNA Vaccination: A
1052 Meta-Analysis and Systematic Review. Cureus 2021;13:e19240. doi:
1053 10.7759/cureus.19240.
1054 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641964/>.
1055
- 1056 32 Lv M, Luo X, Shen Q, Lei R, Liu X, Liu E, et al. Safety, Immunogenicity, and
1057 Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review.
1058 Vaccines (Basel) 2021;9:1102. <https://www.mdpi.com/2076-393X/9/10/1102/htm>.
1059
- 1060 33 Ismail II, Salama S. A systematic review of cases of CNS demyelination
1061 following COVID-19 vaccination. J Neuroimmunol 2022;362:577765. doi:
1062 10.1016/j.jneuroim.2021.577765.
1063 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577051/>.
1064
- 1065 34 Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.
1066 Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.
1067 N Engl J Med 2021;385:1761-73. doi: 10.1056/NEJMoa2110345.
1068 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461570/>.
1069
- 1070 35 Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al.
1071 Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S. N Engl J Med
1072 2022;386:847-60. doi: 10.1056/NEJMoa2117608.
1073 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8849184/>.
1074
- 1075 36 Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, et al. Phase
1076 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N Engl J
1077 Med 2021;385:2348-60. doi: 10.1056/NEJMoa2105290.
1078 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522798/>.
1079
- 1080 37 Khobragade A, Bhate S, Ramaiah V, Deshpande S, Giri K, Phophle H, et al.
1081 Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D):
1082 the interim efficacy results of a phase 3, randomised, double-blind, placebo-
1083 controlled study in India. Lancet 2022;399:1313-21. doi: 10.1016/S0140-
1084 6736(22)00151-9. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970574/>.
1085
- 1086 38 Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and
1087 Efficacy of NVX-CoV2373 Covid-19 Vaccine. N Engl J Med 2021;385:1172-83. doi:
1088 10.1056/NEJMoa2107659.
1089 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262625/>.
1090
- 1091 39 Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, et
1092 al. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
1093 N Engl J Med. 2022;386:531-43. doi: 10.1056/NEJMoa2116185.
1094 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693692/>.
1095
- 1096 40 Fadlyana E, Rusmil K, Tarigan R, Rahmadi AR, Prodjosoewojo S, Sofiatin Y, et
1097 al. A phase III, observer-blind, randomized, placebo-controlled study of the
1098

- 1099 efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in
1100 healthy adults aged 18-59 years: An interim analysis in Indonesia. Vaccine
1101 2021;39:6520-28. doi: 10.1016/j.vaccine.2021.09.052.
1102 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461222/>.
1103
- 1104 41 Hsieh SM, Liu MC, Chen YH, Lee WS, Hwang SJ, Cheng SH, et al. Safety and
1105 immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2
1106 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-
1107 blind, randomised, placebo-controlled phase 2 trial in Taiwan. Lancet Respir Med
1108 2021;9:1396-1406. doi: 10.1016/S2213-2600(21)00402-1.
1109 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514195/>.
1110
- 1111 42 Kulkarni PS, Padmapriyadarsini C, Vekemans J, Bavdekar A, Gupta M, Kulkarni
1112 P, et al. A phase 2/3, participant-blind, observer-blind, randomised, controlled
1113 study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-
1114 19 vaccine) in adults in India. EClinicalMedicine 2021;42:101218. doi:
1115 10.1016/j.eclinm.2021.101218.
1116 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8629682/>.
1117
- 1118 43 Moreira ED Jr, Kitchin N, Xu X, Dychter SS, Lockhart S, Gurtman A, et al. Safety
1119 and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. N Engl J Med
1120 2022;386:1910-21. doi: 10.1056/NEJMoa2200674.
1121 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006787/>.
1122
- 1123 44 Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety
1124 and immunogenicity of seven COVID-19 vaccines as a third dose (booster)
1125 following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST):
1126 a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet
1127 2021;398:2258-76. doi: 10.1016/S0140-6736(21)02717-3.
1128 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639161/>.
1129
- 1130 45 Ali K, Berman G, Zhou H, Deng W, Faughnan V, Coronado-Voges M, et al.
1131 Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. N Engl J Med
1132 2021;385:2241-51. doi: 10.1056/NEJMoa2109522.
1133 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385554/>.
1134
- 1135 46 Frenck RW Jr, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al.
1136 Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in
1137 Adolescents. N Engl J Med 2021;385:239-50. doi: 10.1056/NEJMoa2107456.
1138 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8174030/>.
1139
- 1140 47 Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and
1141 immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people
1142 younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial.
1143 Lancet Infect Dis 2022;22:196-208. doi: 10.1016/S1473-3099(21)00462-X.
1144 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443232/>.
1145
- 1146 48 Bardenheier BH, Gravenstein S, Blackman C, Gutman R, Sarkar IN, Feifer RA,
1147 et al. Adverse events following mRNA SARS-CoV-2 vaccination among U.S.

1148 nursing home residents. Vaccine 2021;39:3844-51. DOI:
1149 [10.1016/j.vaccine.2021.05.088](https://doi.org/10.1016/j.vaccine.2021.05.088).
1150
1151 49 Hippisley-Cox J, Patone M, Mei XW, Saatci D, Dixon S, Khunti K, et al. Risk of
1152 thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-
1153 CoV-2 positive testing: self-controlled case series study. BMJ 2021;374:n1931.
1154 doi: 10.1136/bmj.n1931.
1155 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388189/>.
1156
1157 50 Simpson CR, Shi T, Vasileiou E, Katikireddi SV, Kerr S, Moore E, et al. First-
1158 dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic,
1159 thromboembolic and hemorrhagic events in Scotland. Nat Med 2021;27:1290-7.
1160 doi: 10.1038/s41591-021-01408-4.
1161 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282499/>.
1162
1163 51 Jeet Kaur RJ, Dutta S, Charan J, Bhardwaj P, Tandon A, Yadav D, et al.
1164 Cardiovascular Adverse Events Reported from COVID-19 Vaccines: A Study
1165 Based on WHO Database. Int J Gen Med 2021;14:3909-27. doi:
1166 10.2147/IJGM.S324349.
1167 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326931/>.
1168
1169 52 Whiteley WN, Ip S, Cooper JA, Bolton T, Keene S, Walker V, et al. Association of
1170 COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or
1171 thrombocytopenic events: A population-based cohort study of 46 million adults
1172 in England. PLoS Med 2022;19:e1003926.
1173 <https://doi.org/10.1371/journal.pmed.1003926>.
1174
1175 53 Li X, Burn E, Duarte-Salles T, Yin C, Reich C, Delmestri A, et al. Comparative
1176 risk of thrombosis with thrombocytopenia syndrome or thromboembolic events
1177 associated with different covid-19 vaccines: international network cohort study
1178 from five European countries and the US. BMJ 2022;379:e071594. doi:
1179 10.1136/bmj-2022-071594.
1180 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9597610/>.
1181
1182 54 Hviid A, Hansen JV, Thieson EM, Wohlfahrt J. Association of AZD1222 and
1183 BNT162b2 COVID-19 vaccination with thromboembolic and thrombocytopenic
1184 events in frontline personnel: a retrospective cohort study. Ann Intern Med
1185 2022;175:541-6. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8805866/>.
1186
1187 55 Cari L, Alhosseini MN, Fiore P, Pierno S, Pacor S, Bergamo A, et al.
1188 Cardiovascular, neurological, and pulmonary events following vaccination with
1189 the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of
1190 European data. J Autoimmun 2021;125:102742. doi:
1191 10.1016/j.jaut.2021.102742.
1192 [https://www.sciencedirect.com/science/article/pii/S0896841121001505?via%](https://www.sciencedirect.com/science/article/pii/S0896841121001505?via%3DiHub)
1193 [3DiHub](https://www.sciencedirect.com/science/article/pii/S0896841121001505?via%3DiHub).
1194
1195 56 Cari L, Fiore P, Naghavi Alhosseini M, Sava G, Nocentini G. Blood clots and
1196 bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis

1197 of European data. *J Autoimmun* 2021;122:102685. doi:
1198 10.1016/j.jaut.2021.102685.
1199 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220408/>.
1200
1201 57 Jabagi MJ, Botton J, Bertrand M, Weill A, Farrington P, Zureik M, et al.
1202 Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA
1203 COVID-19 Vaccine in People Aged 75 Years or Older. *JAMA* 2022;327:80-2. doi:
1204 10.1001/jama.2021.21699.
1205 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609457/>.
1206
1207 58 Pawlowski C, Rincón-Hekking J, Awasthi S, Pandey V, Lenehan P,
1208 Venkatakrishnan AJ, et al. Cerebral Venous Sinus Thrombosis is not Significantly
1209 Linked to COVID-19 Vaccines or Non-COVID Vaccines in a Large Multi-State
1210 Health System. *J Stroke Cerebrovasc Dis* 2021;30:105923. doi:
1211 10.1016/j.jstrokecerebrovasdis.2021.105923.
1212 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494567/>.
1213
1214 59 Abbattista M, Martinelli I, Peyvandi F. Comparison of adverse drug reactions
1215 among four COVID-19 vaccines in Europe using the EudraVigilance database:
1216 Thrombosis at unusual sites. *J Thromb Haemost* 2021;19:2554-8. doi:
1217 10.1111/jth.15493. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420446/>.
1218
1219 60 Showkathali R, Yalamanchi R, Narra L, Vinayagamoorthy N, Gunasekaran S,
1220 Nayak R, et al. Coronary thrombo-embolic events after Covid-19 vaccination- a
1221 single centre study. *Indian Heart J* 2022;74:131-4. doi:
1222 10.1016/j.ihj.2022.01.002.
1223 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8808476/>.
1224
1225 61 Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, et al.
1226 Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2
1227 Infection by Age and Sex. *Circulation* 2022;146:743-54. doi:
1228 10.1161/CIRCULATIONAHA.122.059970.
1229 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9439633/>.
1230
1231 62 Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, et al.
1232 Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with
1233 COVID-19 vaccination or SARS-CoV-2 infection. *Nat Med* 2022;28:410-22. doi:
1234 10.1038/s41591-021-01630-0.
1235 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863574/>.
1236
1237 63 Chouchana L, Blet A, Al-Khalaf M, Kafil TS, Nair G, Robblee J, et al. Features of
1238 Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a
1239 Global Level. *Clin Pharmacol Ther* 2022;111:605-13. doi: 10.1002/cpt.2499.
1240 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015432/>.
1241
1242 64 Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, et al. Myocarditis Cases
1243 Reported After mRNA-Based COVID-19 Vaccination in the US From December
1244 2020 to August 2021. *JAMA* 2022;327:331-40. doi: 10.1001/jama.2021.24110.
1245 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790664/>.

1246
1247 65 Li M, Yuan J, Lv G, Brown J, Jiang X, Lu ZK. Myocarditis and Pericarditis
1248 following COVID-19 Vaccination: Inequalities in Age and Vaccine Types. J Pers
1249 Med 2021;11:1106. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624452/>.
1250
1251 66 Patone M, Handunnetthi L, Saatci D, Pan J, Katikireddi SV, Razvi S, et al.
1252 Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-
1253 2 infection. Nat Med 2021;27:2144-2153. doi: 10.1038/s41591-021-01556-7.
1254 <https://www.nature.com/articles/s41591-021-01556-7>.
1255
1256 67 Li X, Raventós B, Roel E, Pistillo A, Martinez-Hernandez E, Delmestri A, et al.
1257 Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of
1258 immune mediated neurological events: population based cohort and self-
1259 controlled case series analysis. BMJ 2022;376:e068373. doi: 10.1136/bmj-2021-
1260 068373.
1261 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924704/>.
1262
1263 68 Shemer A, Pras E, Einan-Lifshitz A, Dubinsky-Pertzov B, Hecht I. Association
1264 of COVID-19 Vaccination and Facial Nerve Palsy: A Case-Control Study. JAMA
1265 Otolaryngol Head Neck Surg 2021;147:739-43. doi: 10.1001/jamaoto.2021.1259.
1266 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227442/>.
1267
1268 69 Shibli R, Barnett O, Abu-Full Z, Gronich N, Najjar-Debbiny R, Doweck I, et al.
1269 Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine
1270 and Bell's palsy: a population-based study. Lancet Reg Health Eur
1271 2021;11:100236. doi: 10.1016/j.lanepe.2021.100236.
1272 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566165/>.
1273
1274 70 Shasha D, Bareket R, Sikron FH, Gertel O, Tsamir J, Dvir D, et al. Real-world
1275 safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine: historical cohort study.
1276 Clin Microbiol Infect 2022;28:130-4. doi: 10.1016/j.cmi.2021.09.018.
1277 <https://pubmed.ncbi.nlm.nih.gov/34592420/>.
1278
1279 71 Nosedà R, Ripellino P, Ghidossi S, Bertoli R, Ceschi A. Reporting of Acute
1280 Inflammatory Neuropathies with COVID-19 Vaccines: Subgroup
1281 Disproportionality Analyses in Vigibase. Vaccines (Basel) 2021;9:1022. doi:
1282 10.3390/vaccines9091022.
1283 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473382/>.
1284
1285 72 Dutta S, Kaur R, Charan J, Bhardwaj P, Ambwani SR, Babu S, et al. Analysis of
1286 Neurological Adverse Events Reported in Vigibase From COVID-19 Vaccines.
1287 Cureus 2022;14:e21376. doi: 10.7759/cureus.21376.
1288 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852793/>.
1289
1290 73 Formeister EJ, Wu MJ, Chari DA, Meek R 3rd, Rauch SD, Remenschneider AK,
1291 et al. Assessment of Sudden Sensorineural Hearing Loss After COVID-19
1292 Vaccination. JAMA Otolaryngol Head Neck Surg 2022;148:307-15. doi:
1293 10.1001/jamaoto.2021.4414.
1294 <https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2789496>.

1295
1296 74 Efrati S, Catalogna M, Abu Hamad R, Hadanny A, Bar-Chaim A, Benveniste-
1297 Levkovitz P, et al. Safety and humoral responses to BNT162b2 mRNA vaccination
1298 of SARS-CoV-2 previously infected and naive populations. Sci Rep
1299 2021;11:16543. doi: 10.1038/s41598-021-96129-6.
1300 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8367980/>.
1301
1302 75 Chalkias S, Schwartz H, Nestorova B, Feng J, Chang Y, Zhou H, et al. Safety and
1303 Immunogenicity of a 100 µg mRNA-1273 Vaccine Booster for Severe Acute
1304 Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). medRxiv [Preprint] 2022
1305 Mar 7:2022.03.04.22271830. doi: 10.1101/2022.03.04.22271830.
1306 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923111/>.
1307
1308 76 Hause AM, Baggs J, Gee J, Marquez P, Myers TR, Shimabukuro TT, et al. Safety
1309 Monitoring of an Additional Dose of COVID-19 Vaccine - United States, August
1310 12-September 19, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1379-84. doi:
1311 10.15585/mmwr.mm7039e4.
1312 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486391/>.
1313
1314 77 Mitchell J, Yue QY. Appendicitis as a possible safety signal for the COVID-19
1315 vaccines. Vaccine X 2021;9:100122. doi: 10.1016/j.jvacx.2021.100122.
1316 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565092/>.
1317
1318 78 Kildegaard H, Ladebo L, Andersen JH, Jensen PB, Rasmussen L, Damkier P, et
1319 al. Risk of Appendicitis After mRNA COVID-19 Vaccination in a Danish
1320 Population. JAMA Intern Med 2022;182:684-6. doi:
1321 10.1001/jamainternmed.2022.1222.
1322 <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2791667>.
1323
1324 79 Benn CS, Nielsen S, Scholtz-Buchholzer F, Netea MG, Aaby P. Randomised
1325 clinical trials of COVID-19 vaccines: do adenovirus-vector vaccines have
1326 beneficial non-specific effects? Lancet preprint 2022; 5 April.
1327 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4072489.
1328
1329 80 COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite
1330 possible link to rare blood clots with low blood platelets. EMA 2021 March 18.
1331 [https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-](https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots)
1332 [still-outweigh-risks-despite-possible-link-rare-blood-clots](https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots) (accessed 2022 Nov
1333 30).
1334
1335 81 Jørgensen FR, Gøtzsche PC, Hein P, Jensen CM, Nielsen BM, Nielsen FM, et al.
1336 Naproxen (Naprosyn) og mobilisering ved behandling af akut ankeldistorsion
1337 [Naproxen (Naprosyn) and mobilization in the treatment of acute ankle sprains].
1338 Ugeskr Laeger 1986;148:1266-8. <https://pubmed.ncbi.nlm.nih.gov/3523914/>.
1339
1340 82 Gøtzsche PC. Big marketing hoax: Non-steroidal, anti-inflammatory drugs
1341 (NSAIDs) are not anti-inflammatory. Copenhagen: Institute for Scientific
1342 Freedom 2022 Nov 10. <https://www.scientificfreedom.dk/2022/11/10/big->

- 1343 [marketing-hoax-non-steroidal-anti-inflammatory-drugs-nsaids-are-not-anti-](#)
- 1344 [inflammatory/](#) (accessed 2022 Nov 30).
- 1345
- 1346 83 Gøtzsche PC. Sensitivity of effect variables in rheumatoid arthritis: a meta-
- 1347 analysis of 130 placebo controlled NSAID trials. J Clin Epidemiol 1990;43:1313-
- 1348 8. DOI: [10.1016/0895-4356\(90\)90097-9](https://doi.org/10.1016/0895-4356(90)90097-9).
- 1349
- 1350 84 Gøtzsche PC. Vaccines: truth, lies, and controversy. New York: Skyhorse;
- 1351 2021.
- 1352
- 1353 85 Doshi P. Covid-19 vaccines: In the rush for regulatory approval, do we need
- 1354 more data? BMJ 2021;373:n1244 doi:10.1136/bmj.n1244.
- 1355 <https://www.bmj.com/content/373/bmj.n1244>.
- 1356
- 1357 86 FDA Authorizes Booster Dose of Pfizer-BioNTech COVID-19 Vaccine for
- 1358 Certain Populations. 2021 Sept 22. [https://www.fda.gov/news-events/press-](https://www.fda.gov/news-events/press-announcements/fda-authorizes-booster-dose-pfizer-biontech-covid-19-vaccine-certain-populations)
- 1359 [announcements/fda-authorizes-booster-dose-pfizer-biontech-covid-19-vaccine-](https://www.fda.gov/news-events/press-announcements/fda-authorizes-booster-dose-pfizer-biontech-covid-19-vaccine-certain-populations)
- 1360 [certain-populations](https://www.fda.gov/news-events/press-announcements/fda-authorizes-booster-dose-pfizer-biontech-covid-19-vaccine-certain-populations) (accessed 2022 Nov 30).
- 1361
- 1362 87 Comirnaty and Spikevax: EMA recommendations on extra doses and boosters.
- 1363 2021 Oct 4. [https://www.ema.europa.eu/en/news/comirnaty-spikevax-ema-](https://www.ema.europa.eu/en/news/comirnaty-spikevax-ema-recommendations-extra-doses-boosters)
- 1364 [recommendations-extra-doses-boosters](https://www.ema.europa.eu/en/news/comirnaty-spikevax-ema-recommendations-extra-doses-boosters) (accessed 2022 Nov 30).
- 1365
- 1366 88 Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al.
- 1367 Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–
- 1368 Associated Emergency Department and Urgent Care Encounters and
- 1369 Hospitalizations Among Adults During Periods of Delta and Omicron Variant
- 1370 Predominance — VISION Network, 10 States, August 2021–January 2022.
- 1371 MMWR 2022;71:255-63. doi: <http://dx.doi.org/10.15585/mmwr.mm7107e2>.
- 1372
- 1373 89 Burger L, Aripaka P. EU drugs regulator says data supports vaccine boosters
- 1374 after three months. Reuters. 2021 Dec 9.
- 1375 [https://www.reuters.com/world/europe/eu-drugs-regulator-says-data-](https://www.reuters.com/world/europe/eu-drugs-regulator-says-data-supports-vaccine-boosters-after-three-months-2021-12-09/)
- 1376 [supports-vaccine-boosters-after-three-months-2021-12-09/](https://www.reuters.com/world/europe/eu-drugs-regulator-says-data-supports-vaccine-boosters-after-three-months-2021-12-09/) (accessed 2022 Nov
- 1377 30).
- 1378
- 1379 90 Reuters. EU drug regulator expresses doubt on need for fourth booster dose.
- 1380 2022 Jan 11. [https://www.reuters.com/business/healthcare-](https://www.reuters.com/business/healthcare-pharmaceuticals/eu-drug-regulator-says-more-data-needed-impact-omicron-vaccines-2022-01-11/)
- 1381 [pharmaceuticals/eu-drug-regulator-says-more-data-needed-impact-omicron-](https://www.reuters.com/business/healthcare-pharmaceuticals/eu-drug-regulator-says-more-data-needed-impact-omicron-vaccines-2022-01-11/)
- 1382 [vaccines-2022-01-11/](https://www.reuters.com/business/healthcare-pharmaceuticals/eu-drug-regulator-says-more-data-needed-impact-omicron-vaccines-2022-01-11/) (accessed 2022 Nov 30).
- 1383
- 1384 91 Skowronski DM, De Serres G, Crowcroft NS, Janjua NZ, Boulianne N, Hottes TS,
- 1385 et al. Association between the 2008-09 seasonal influenza vaccine and pandemic
- 1386 H1N1 illness during Spring-Summer 2009: four observational studies from
- 1387 Canada. PLoS Med 2010;7:e1000258. DOI: [10.1371/journal.pmed.1000258](https://doi.org/10.1371/journal.pmed.1000258).
- 1388
- 1389 92 Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, et al.
- 1390 Evaluating non-randomised intervention studies. Health Technol Assess
- 1391 2003;7:iii-x, 1-173. DOI: [10.3310/hta7270](https://doi.org/10.3310/hta7270).

1392
1393 93 Li X, Ostroplets A, Makadia R, Shoaibi A, Rao G, Sena AG, et al. Characterising
1394 the background incidence rates of adverse events of special interest for covid-19
1395 vaccines in eight countries: multinational network cohort study. BMJ
1396 2021;373:n1435. DOI: [10.1136/bmj.n1435](https://doi.org/10.1136/bmj.n1435).
1397
1398 94 Wadman M. Scientists quit journal board, protesting 'grossly irresponsible'
1399 study claiming COVID-19 vaccines kill. Science 2021 July 1.
1400 [https://www.science.org/content/article/scientists-quit-journal-board-](https://www.science.org/content/article/scientists-quit-journal-board-protesting-grossly-irresponsible-study-claiming-covid-19)
1401 [protesting-grossly-irresponsible-study-claiming-covid-19](https://www.science.org/content/article/scientists-quit-journal-board-protesting-grossly-irresponsible-study-claiming-covid-19) (accessed 2022 Nov
1402 30).
1403
1404 95 Walach H, Klement RJ, Aukema W. Retracted: The Safety of COVID-19
1405 Vaccinations - We Should Rethink the Policy. Vaccines (Basel) 2021 Jun
1406 24;9(7):693. doi: 10.3390/vaccines9070693. Retraction in: Vaccines (Basel)
1407 2021 Jul 02;9(7):null.
1408 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294615/>.
1409
1410 96 Sultana A, Shahriar S, Tahsin MR, Mim SR, Fatema KR, Saha A, et al. A
1411 Retrospective Cross-Sectional Study Assessing Self-Reported Adverse Events
1412 following Immunization (AEFI) of the COVID-19 Vaccine in Bangladesh. Vaccines
1413 (Basel) 2021;9:1090. doi: 10.3390/vaccines9101090.
1414 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538494/>.
1415
1416 97 Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al.
1417 The PRISMA statement for reporting systematic reviews and meta-analyses of
1418 studies that evaluate healthcare interventions: explanation and elaboration. BMJ
1419 2009;339:b2700. DOI: [10.1136/bmj.b2700](https://doi.org/10.1136/bmj.b2700).
1420
1421 98 Sun CLF, Jaffe E, Levi R. Increased emergency cardiovascular events among
1422 under-40 population in Israel during vaccine rollout and third COVID-19 wave.
1423 Sci Rep 2022;12:6978. <https://doi.org/10.1038/s41598-022-10928-z>.
1424
1425 99 Reuters Fact Check. Fact Check-Study using Israeli emergency services data
1426 does not prove COVID-19 vaccines cause heart problems. 2022 May 10.
1427 <https://www.reuters.com/article/factcheck-study-emergency-idUSL2N2X21LM>
1428 (accessed 2022 Dec 2).
1429
1430 100 Morgan J, Roper MH, Sperling L, Schieber RA, Heffelfinger JD, Casey CG, et al.
1431 Myocarditis, pericarditis, and dilated cardiomyopathy after smallpox vaccination
1432 among civilians in the United States, January-October 2003. Clin Infect Dis
1433 2008;46 Suppl 3:S242-50. doi: 10.1086/524747.
1434 [https://academic.oup.com/cid/article/46/Supplement_3/S242/575828?login=f](https://academic.oup.com/cid/article/46/Supplement_3/S242/575828?login=false)
1435 [alse](https://academic.oup.com/cid/article/46/Supplement_3/S242/575828?login=false).
1436
1437 101 Langmuir AD. Guillain-Barré syndrome: the swine influenza virus vaccine
1438 incident in the United States of America, 1976-77: preliminary communication. J
1439 R Soc Med 1979;72:660-9. doi: 10.1177/014107687907200908.
1440 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1436986/>.

1441
1442 102 Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundmanet J, et
1443 al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the
1444 incidence of childhood narcolepsy in Finland. PLoS One 2012;7:e33536.
1445 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3314666/>.
1446
1447 103 Vogel G. Why a pandemic flu shot caused narcolepsy. Science 2015 July 1.
1448 [https://www.science.org/content/article/why-pandemic-flu-shot-caused-](https://www.science.org/content/article/why-pandemic-flu-shot-caused-narcolepsy)
1449 [narcolepsy](https://www.science.org/content/article/why-pandemic-flu-shot-caused-narcolepsy) (accessed 2022 Dec 2).
1450
1451 104 Jørgensen L, Gøtzsche PC, Jefferson T. Benefits and harms of the human
1452 papillomavirus (HPV) vaccines: systematic review with meta-analyses of trial
1453 data from clinical study reports. Syst Rev 2020;9:43. DOI: [10.1186/s13643-019-](https://doi.org/10.1186/s13643-019-0983-y)
1454 [0983-y](https://doi.org/10.1186/s13643-019-0983-y).
1455
1456 105 Gøtzsche PC, Jørgensen KJ. EMA's mishandling of an investigation into
1457 suspected serious neurological harms of HPV vaccines. BMJ Evid Based Med
1458 2022;27:7-10. <http://dx.doi.org/10.1136/bmjebm-2020-111470>.
1459
1460 106 React 19. Covid Vaccine Persistent Symptoms Survey. 2022 Oct 5.
1461 [https://www.react19.org/post/persistent-neurological-symptoms-patient-](https://www.react19.org/post/persistent-neurological-symptoms-patient-survey)
1462 [survey](https://www.react19.org/post/persistent-neurological-symptoms-patient-survey) (accessed 2022 Nov 30).
1463
1464 107 Safavi F, Gustafson L, Walitt B, Lehky T, Dehbashi S, Wiebold A, et al.
1465 Neuropathic symptoms with SARS-CoV-2 vaccination. medRxiv
1466 2022.05.16.22274439; doi: <https://doi.org/10.1101/2022.05.16.22274439>.
1467 <https://www.medrxiv.org/content/10.1101/2022.05.16.22274439v1>.
1468
1469 108 Mehlsen J, Brinth L, Pors K, Varming K, Wallukat G, Olsen RKJ. Autoimmunity
1470 in patients reporting long-term complications after exposure to human
1471 papilloma virus vaccination. J Autoimmun 2022;133:102921. doi:
1472 10.1016/j.jaut.2022.102921.
1473 [https://www.sciencedirect.com/science/article/abs/pii/S0896841122001299?](https://www.sciencedirect.com/science/article/abs/pii/S0896841122001299?via%3Dihub)
1474 [via%3Dihub](https://www.sciencedirect.com/science/article/abs/pii/S0896841122001299?via%3Dihub).
1475
1476 109 Kedor C, Freitag H, Meyer-Arndt L, Wittke K, Hanitsch LG, Zoller T, et al. A
1477 prospective observational study of post-COVID-19 chronic fatigue syndrome
1478 following the first pandemic wave in Germany and biomarkers associated with
1479 symptom severity. Nat Commun 2022;13:5104. doi: 10.1038/s41467-022-
1480 32507-6. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426365/>.
1481
1482 110 Wallukat G, Hohberger B, Wenzel K, Fürst J, Schulze-Rothe S, Wallukat A, et
1483 al. Functional autoantibodies against G-protein coupled receptors in patients
1484 with persistent Long-COVID-19 symptoms. J Transl Autoimmun 2021;4:100100.
1485 doi: 10.1016/j.jtauto.2021.100100.
1486 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049853/>.
1487
1488 111 Román GC, Gracia F, Torres A, Palacios A, Gracia K, Harris D. Acute
1489 Transverse Myelitis (ATM): Clinical Review of 43 Patients With COVID-19-

1490 Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the
1491 ChAdOx1 nCoV-19 Vaccine (AZD1222). *Front Immunol* 2021;12:653786. DOI:
1492 [10.3389/fimmu.2021.653786](https://doi.org/10.3389/fimmu.2021.653786).
1493
1494 112 Onakpoya IJ. Rare adverse events in clinical trials: understanding the rule of
1495 three. *BMJ Evid Based Med* 2018;23:6. DOI: [10.1136/ebmed-2017-110885](https://doi.org/10.1136/ebmed-2017-110885).
1496
1497 113 Yousaf AR, Cortese MM, Taylor AW, Broder KR, Oster ME, Wong JM, et al.
1498 Reported cases of multisystem inflammatory syndrome in children aged 12-20
1499 years in the USA who received a COVID-19 vaccine, December, 2020, through
1500 August, 2021: a surveillance investigation. *Lancet Child Adolesc Health*
1501 2022;6:303-12. doi: 10.1016/S2352-4642(22)00028-1.
1502 [https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642\(22\)00028-](https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(22)00028-1/fulltext)
1503 [1/fulltext](https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(22)00028-1/fulltext).
1504
1505 114 Benn CS, Fisker AB, Aaby P (eds.). *Bandim Health Project, 1978-2018. Forty*
1506 *years of contradicting conventional wisdom*. København: Statens Seruminstitut
1507 2018. [https://www2.bandim.dk/wp-content/uploads/2021/03/Jubilumsbog-](https://www2.bandim.dk/wp-content/uploads/2021/03/Jubilumsbog-2018.pdf)
1508 [2018.pdf](https://www2.bandim.dk/wp-content/uploads/2021/03/Jubilumsbog-2018.pdf) (accessed 2022 Nov 30).
1509
1510 115 Demasi M. FDA urged to publish follow-up studies on covid-19 vaccine
1511 safety signals. *BMJ* 2022;379:o2527. doi: <https://doi.org/10.1136/bmj.o2527>.
1512
1513 116 Montano D. Frequency and associations of adverse reactions of COVID-19
1514 vaccines reported to pharmacovigilance systems in the European Union and the
1515 United States. *Front Public Health* 2022;9:756633.
1516 <https://www.frontiersin.org/articles/10.3389/fpubh.2021.756633/full>.
1517